scholarly journals A Minimal Physiologically‐Based Pharmacokinetic Model for Tacrolimus in Living‐Donor Liver Transplantation: Perspectives Related to Liver Regeneration and the cytochrome P450 3A5 (CYP3A5) Genotype

2019 ◽  
Vol 8 (8) ◽  
pp. 587-595 ◽  
Author(s):  
Kotaro Itohara ◽  
Ikuko Yano ◽  
Tetsunori Tsuzuki ◽  
Miwa Uesugi ◽  
Shunsaku Nakagawa ◽  
...  
Keyword(s):  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Pharmacokinetic Model ◽  
Physiologically Based Pharmacokinetic Model ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Physiologically Based Pharmacokinetic ◽  
Cyp3a5 Genotype ◽  
Physiologically Based ◽  
Cytochrome P450 3A5

Adult-to-Adult Living-Donor Liver Transplantation

Swiss Surgery ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 227-236 ◽  
Author(s):  
Majno ◽  
Mentha ◽  
Berney ◽  
Bühler ◽  
Giostra ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Therapeutic Option ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Multidisciplinary Program ◽  
First Case ◽  
Living Donor Transplantation ◽  
The Right

Living donor liver transplantation is a relatively new procedure in which the right side of the liver is harvested in a healthy donor and transplanted into a recipient. After the first case in 1994, over 3000 cases have been done worldwide. This review summarizes the reasons why the procedure is needed, describes its main technical aspects, highlights the boundaries in which it can be done safely, summarizes the current experience worldwide and describes the main points of the program in our unit. We argue that living-donor transplantation is a viable alternative to a long time on the waiting list for several patients, and it can be performed safely and successfully provided that all precautions are undertaken to minimize the risks in the donor and to increase the chances of a good outcome in the recipients. If these prerequisites are met, and within the framework of a structured multidisciplinary program, we believe that living-donor liver transplantation should be funded by health insurances as a recognized therapeutic option.

Sign in / Sign up

Export Citation Format

Share Document